

PRESCRIBING INFORMATION

Lidocaine Hydrochloride Injection USP 10 mg/mL, 20 mg/mL

Sterile Solution

Local Anesthetic

Pfizer Canada ULC
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5

Date of Revision:
July 2, 2019

Submission Control No: 222456

TABLE OF CONTENTS

PART I: HEALTH PROFESSIONAL INFORMATION.....	3
SUMMARY PRODUCT INFORMATION.....	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS.....	4
WARNINGS AND PRECAUTIONS.....	4
ADVERSE REACTIONS.....	11
DRUG INTERACTIONS.....	12
DOSAGE AND ADMINISTRATION.....	15
OVERDOSAGE.....	20
ACTION AND CLINICAL PHARMACOLOGY.....	22
STORAGE AND STABILITY.....	23
SPECIAL HANDLING INSTRUCTIONS.....	24
DOSAGE FORMS, COMPOSITION AND PACKAGING.....	24
PART II: SCIENTIFIC INFORMATION.....	26
PHARMACEUTICAL INFORMATION.....	26
REFERENCES.....	27
PART III: CONSUMER INFORMATION.....	28

Lidocaine Hydrochloride Injection USP

10 mg/mL, 20 mg/mL

Sterile Solution

Local Anesthetic

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Non-medicinal Ingredients
Parenteral	Sterile solutions of Lidocaine Hydrochloride Injection USP contains 10 and 20 mg/mL lidocaine hydrochloride.	<u>Multidose Vials:</u> All multidose vials of lidocaine hydrochloride contain methylparaben. <i>For a complete listing, see Dosage Forms, Composition and Packaging section.</i>

INDICATIONS AND CLINICAL USE

Adults (>18 years of age):

Lidocaine Hydrochloride Injection USP is indicated for production of local or regional anesthesia by:

- Infiltration techniques including percutaneous injection;
- Peripheral nerve block techniques such as brachial plexus and intercostal blocks; and
- Central neural techniques, including epidural and caudal blocks,

when the accepted procedures for these techniques, as described in standard textbooks, are observed.

Geriatrics (> 65 years of age):

Elderly patients should be given reduced doses commensurate with their age and physical condition (see DOSAGE AND ADMINISTRATION: Special Populations).

Pediatrics (<18 years of age):

Children should be given reduced doses commensurate with their age, weight and physical condition (see DOSAGE AND ADMINISTRATION: Special Populations).

Lidocaine should be used with caution in children younger than two years of age as there are insufficient data to support the safety and efficacy of this product in this patient population at this time.

CONTRAINDICATIONS

Lidocaine Hydrochloride Injection USP is contraindicated in:

- Patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of the solution (see DOSAGE FORMS, COMPOSITION AND PACKAGING).
- Patients with a known history of hypersensitivity to methylparaben and/or propylparaben (preservatives used in multidose solutions), or to their metabolite para-aminobenzoic acid (PABA).

Solutions of lidocaine containing parabens should also be avoided in patients with a history of allergic reactions to ester local anesthetics, which are metabolized to PABA.

Lidocaine Hydrochloride Injection USP containing antimicrobial preservatives (e.g., methylparaben) should not be used for epidural or spinal anesthesia, or for any route of administration that would introduce solution into the cerebrospinal fluid because the safety of these agents has not been established with regard to intrathecal injection, either intentional or accidental. The solution should not be administered intra-ocularly or retro-ocularly.

Lidocaine Hydrochloride Injection USP containing antimicrobial preservatives should not be used in doses greater than 15 mL for other types of blockades.

WARNINGS AND PRECAUTIONS

General

LOCAL ANESTHETICS SHOULD ONLY BE EMPLOYED BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES THAT MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED AND THEN ONLY AFTER ENSURING THE IMMEDIATE AVAILABILITY OF OXYGEN, OTHER RESUSCITATIVE DRUGS, CARDIOPULMONARY EQUIPMENT AND THE PERSONNEL NEEDED FOR PROPER MANAGEMENT OF TOXIC REACTIONS AND RELATED EMERGENCIES (see also ADVERSE REACTIONS and OVERDOSAGE). DELAY IN PROPER MANAGEMENT OF DOSE-RELATED TOXICITY, UNDERVENTILATION FROM ANY CAUSE, AND/OR ALTERED SENSITIVITY MAY LEAD TO THE DEVELOPMENT OF ACIDOSIS, CARDIAC ARREST AND POSSIBLY, DEATH.

AN INTRAVENOUS CANNULA MUST BE INSERTED BEFORE THE LOCAL

ANESTHETIC IS INJECTED FOR NERVE BLOCKS WHICH MAY RESULT IN HYPOTENSION OR BRADYCARDIA, OR WHERE ACUTE SYSTEMIC TOXICITY MAY DEVELOP FOLLOWING INADVERTENT INTRAVASCULAR INJECTION.

THE LOWEST DOSAGE OF LOCAL ANESTHETIC THAT RESULTS IN EFFECTIVE ANESTHESIA OR ANALGESIA SHOULD BE USED TO AVOID HIGH PLASMA LEVELS AND SERIOUS ADVERSE REACTIONS. INJECTIONS SHOULD BE MADE SLOWLY OR IN INCREMENTAL DOSES, WITH FREQUENT ASPIRATIONS BEFORE AND DURING THE INJECTION TO AVOID INTRAVASCULAR INJECTION.

Methemoglobinemia: Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.

Reports of Irreversible Chondrolysis with Intra-articular Infusions of Local Anesthetics Following Surgery: Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of irreversible chondrolysis in patients receiving such infusions. The majority of reported cases of irreversible chondrolysis have involved the shoulder joint; cases of gleno-humeral irreversible chondrolysis have been described in pediatric and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours. The time of onset of symptoms, such as joint pain, stiffness and loss of motion can be variable, but may begin as early as the 2nd month after surgery. Currently, there is no effective treatment for irreversible chondrolysis; patients who experienced irreversible chondrolysis have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement. **Lidocaine Hydrochloride Injection USP should not be used for post-operative intra-articular infusion** (see DOSAGE AND ADMINISTRATION).

Major Peripheral Nerve Blocks: Major peripheral nerve blocks may imply the administration of a large volume of local anesthetic in areas of high vascularity, often close to large vessels where there is an increased risk of intravascular injection and/or rapid systemic absorption which can lead to high plasma concentrations.

Repeat Dosing: Repeated doses of Lidocaine Hydrochloride Injection USP may cause significant increases in blood levels with each repeated dose because of slow accumulation of the drug or its metabolites. Tolerance to elevated blood levels varies with the status of the patient. Debilitated, elderly patients, acutely ill patients and children should be given reduced doses commensurate with their age and physical condition (see DOSAGE AND ADMINISTRATION: Special Populations).

Inflammation and Sepsis: Local anesthetic procedures should not be used when there is inflammation and/or sepsis in the region of the proposed injection.

Malignant Hyperthermia: Many drugs used during the conduct of anesthesia are considered potential triggering agents for familial malignant hyperthermia. It has been shown that the use of amide local anesthetics in malignant hyperthermia patients is safe. However, there is no guarantee that neural blockade will prevent the development of malignant hyperthermia during surgery. It is also difficult to predict the need for supplemental general anesthesia. Therefore, a standard protocol for the management of malignant hyperthermia should be available.

Acute Porphyria: Lidocaine has been shown to be porphyrinogenic in animal models. Lidocaine Hydrochloride Injection USP should only be used in patients with acute porphyria when no safer alternative is available. Appropriate precautions should be taken for all porphyric patients.

Cardiovascular

Lidocaine should be used with caution in patients with bradycardia or impaired cardiovascular function since they may be less able to compensate for functional changes associated with the prolongation of A-V conduction produced by amide-type local anesthetics.

Patients with partial or complete heart block require special attention since local anesthetics may depress myocardial conduction. To reduce the risk of potentially serious adverse reactions, attempts should be made to optimize the patient's condition before major blocks are performed. Dosage should be adjusted accordingly.

Lidocaine should be used with caution in patients in severe shock.

Lumbar and caudal epidural anesthesia should be used with extreme caution in persons with severe hypertension.

Central nerve blocks may cause cardiovascular depression, especially in the presence of hypovolemia. Epidural anesthesia should be used with caution in patients with impaired cardiovascular function.

Epidural anesthesia may lead to hypotension and bradycardia, which should be managed according to patient conditions and standard of anaesthetic care.

Patients treated with antiarrhythmic drugs (e.g., amiodarone, mexiletine) should be under close surveillance and ECG monitoring, since cardiac effects of these drugs and lidocaine may be additive (see DRUG INTERACTIONS).

Peri-Operative Considerations

It is essential that aspiration for blood or cerebrospinal fluid (where applicable) be done prior to injecting any local anesthetics, both the original and all subsequent doses, to avoid intravascular or subarachnoid injection. However, a negative aspiration does not ensure against an intravascular or subarachnoid injection.

The safety and effectiveness of Lidocaine Hydrochloride Injection USP solutions depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies. Standard

textbooks should be consulted for specific techniques and precautions for various regional anesthetic procedures.

Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use (see OVERDOSAGE). During major regional nerve blocks or using large doses, the patient should be in an optimal condition and should have intravenous fluids running via an indwelling catheter to assure a functioning intravenous pathway. The clinician responsible should have adequate and appropriate training in the procedure to be performed, should take the necessary precautions to avoid intravascular injection (see DOSAGE AND ADMINISTRATION), and should be familiar with the diagnosis and treatment of side effects, systemic toxicity and other complications (see ADVERSE REACTIONS and OVERDOSAGE). THE LOWEST DOSAGE THAT RESULTS IN EFFECTIVE ANESTHESIA SHOULD BE USED TO AVOID HIGH PLASMA LEVELS AND SERIOUS ADVERSE EFFECTS. INJECTIONS SHOULD BE MADE SLOWLY, WITH FREQUENT ASPIRATIONS BEFORE AND DURING THE INJECTION TO AVOID INTRAVASCULAR INJECTION.

Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient's state of consciousness should be performed after each local anesthetic injection. It should be kept in mind at such times that restlessness, anxiety, incoherent speech, light-headedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, depression or drowsiness may be early warning signs of central nervous system toxicity.

Head/Neck

Small doses of local anesthetics injected into the head and neck area, including retrobulbar, dental and stellate ganglion blocks, may produce adverse reactions caused by inadvertent injection to an artery. These reactions may be similar to systemic toxicity seen with unintentional intravascular injections of larger doses. Inadvertent injections into an artery can cause cerebral symptoms even at low doses. Confusion, convulsions, respiratory depression and/or respiratory arrest, and cardiovascular stimulation or depression leading to cardiac arrest have been reported. Patients receiving these blocks should have their circulation and respiration monitored and be constantly observed. Resuscitative equipment and personnel for treating adverse reactions should be immediately available. Dosage recommendations should not be exceeded (see DOSAGE AND ADMINISTRATION).

Ophthalmic Surgery: Retrobulbar injections may very occasionally reach the cranial subarachnoid space causing temporary blindness, cardiovascular collapse, apnea, convulsions, etc. These reactions, which may be due to intra-arterial injection or direct injection into the central nervous system via the sheaths of the optic nerve, must be diagnosed and treated promptly.

Retrobulbar and peribulbar injections of local anesthetics carry a low risk of persistent ocular muscle dysfunction. The primary causes include trauma and/or local toxic effects on muscles and/or nerves. The severity of such tissue reactions is related to the degree of trauma, the concentration of the local anesthetic and the duration of exposure of the tissue to the local anesthetic. For this reason, as with all local anesthetics, the lowest effective concentration and

dose of local anesthetic should be used. Vasoconstrictors and other additives may aggravate tissue reactions and should be used only when indicated.

Clinicians who perform retrobulbar blocks should be aware that there have been reports of respiratory arrest following local anesthetic injection. Prior to retrobulbar block, as with all other regional procedures, the immediate availability of equipment, drugs, and personnel to manage respiratory arrest or depression, convulsions, and cardiac stimulation or depression should be assured (see also WARNINGS AND PRECAUTIONS: Injection in Head and Neck Area).

Epidural Anesthesia

During the administration of epidural anesthesia, it is recommended that a test dose be administered initially and that the patient be monitored for central nervous system toxicity and cardiovascular toxicity, as well as for signs of unintended intrathecal administration, before proceeding (see DOSAGE AND ADMINISTRATION). An intravascular injection is still possible even if aspirations for blood are negative. Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect an evanescent rise in systolic blood pressure.

Hepatic

Because amide-type local anesthetics such as lidocaine are metabolized by the liver, these drugs, especially repeated doses, should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at greater risk of developing toxic plasma concentrations.

Neurologic

Lumbar and caudal epidural anesthesia should be used with extreme caution in persons with existing neurological disease or spinal deformities.

Epilepsy: Lidocaine should be used with caution in patients with epilepsy. The risk of central nervous system side effects when using lidocaine in patients with epilepsy is very low, provided that the dose recommendations are followed.

Locomotion and Coordination: When appropriate, patients should be informed in advance that they may experience temporary loss of sensation and motor activity, usually in the lower half of the body, following proper administration of epidural anesthesia.

Besides the direct anesthetic effect, local anesthetics may have a very mild effect on mental function and coordination even in the absence of overt CNS toxicity and may temporarily impair locomotion and alertness.

Renal

Lidocaine is metabolized primarily by the liver to monoethylglycinexylidide (MEGX, which has some CNS activity), and then further to metabolites glycinexylidide (GX) and 2,6-dimethylaniline (see ACTION AND CLINICAL PHARMACOLOGY). Only a small fraction (3%) of lidocaine is excreted unchanged in the urine. The pharmacokinetics of lidocaine

and its main metabolite were not altered significantly in hemodialysis patients (n=4) who received an intravenous dose of lidocaine. Therefore, renal impairment is not expected to significantly affect the pharmacokinetics of lidocaine when Lidocaine Hydrochloride Injection USP is used for short treatment durations, according to dosage instructions (see DOSAGE AND ADMINISTRATION). Caution is recommended when lidocaine is used in patients with severely impaired renal function because lidocaine metabolites may accumulate during long term treatment.

Sensitivity

Lidocaine should be used with caution in persons with known drug sensitivities. Lidocaine solutions are contraindicated in patients with known hypersensitivities to local anesthetics of the amide type, to other components in the formulation, parabens and their metabolite para-aminobenzoic acid (PABA). The use of paraben-containing lidocaine preparations should also be avoided in patients who are allergic to ester local anesthetics (see CONTRAINDICATIONS).

Special Populations

Debilitated patients, acutely ill patients and patients with sepsis should be given reduced doses commensurate with their age, weight and physical condition because they may be more sensitive to systemic effects due to increased blood levels of lidocaine following repeated doses.

Lumbar and caudal epidural anesthesia should be used with extreme caution in persons with septicemia.

Pregnant Women: There are no adequate and well-controlled studies in pregnant women on the effect of lidocaine on the developing fetus.

It is reasonable to assume that a large number of pregnant women and women of child-bearing age have been given lidocaine. No specific disturbances to the reproductive process have so far been reported, e.g., no increased incidence of malformations. However, care should be given during early pregnancy when maximum organogenesis takes place.

Paracervical block can sometimes cause fetal bradycardia/tachycardia, and careful monitoring of the fetal heart rate is necessary.

Labour and Delivery: Local anesthetics rapidly cross the placenta and when used for epidural, paracervical, pudendal or caudal block anesthesia, can cause varying degrees of maternal, fetal and neonatal toxicity. The potential for toxicity depends upon the procedure performed, the type and amount of drug used, and the technique of drug administration. Adverse reactions in the parturient, fetus and neonate involve alterations of the central nervous system, peripheral vascular tone and cardiac function.

Maternal hypotension has resulted from regional anesthesia. Local anesthetics produce vasodilation by blocking sympathetic nerves. Elevating the patient's legs and positioning her on her left side will help prevent decreases in blood pressure. A vasopressor, such as ephedrine, may

be indicated (see WARNINGS AND PRECAUTIONS: Cardiovascular). The fetal heart rate also should be monitored continuously, and electronic fetal monitoring is highly advisable.

Epidural, spinal, paracervical, or pudendal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts. In one study, paracervical block anesthesia was associated with a decrease in the mean duration of first stage labour and facilitation of cervical dilation. However, spinal and epidural anesthesia have also been reported to prolong the second stage of labour by removing the parturient's reflex urge to bear down or by interfering with motor function. The use of obstetrical anesthesia may increase the need for forceps assistance.

Case reports of maternal convulsions and cardiovascular collapse following use of some local anesthetics for paracervical block in early pregnancy (as anesthesia for elective abortion) suggest that systemic absorption under these circumstances may be rapid. Fetal bradycardia may occur in 20 to 30 % of patients receiving paracervical nerve block anesthesia with the amide-type local anesthetics and may be associated with fetal acidosis. Fetal heart rate should always be monitored during paracervical anesthesia. The physician should weigh the possible advantages against risks when considering paracervical block in prematurity, toxemia of pregnancy, and fetal distress. Careful adherence to recommended dosage is of the utmost importance in obstetrical paracervical block. The recommended maximum dose of each drug should not be exceeded. Injection should be made slowly and with frequent aspiration. Allow a 5-minute interval between sides. Failure to achieve adequate analgesia with recommended doses should arouse suspicion of intravascular or fetal intracranial injection. Cases compatible with unintended fetal intracranial injection of local anesthetic solution have been reported following intended paracervical or pudendal block or both. Babies so affected, present with unexplained neonatal depression at birth, which correlates with high local anesthetic serum levels, and often manifest seizures within six hours. Prompt use of supportive measures combined with forced urinary excretion of the local anesthetic has been used successfully to manage this complication.

Nursing Women: Lidocaine and its metabolites are excreted in the breast milk. At therapeutic doses, the quantities of lidocaine and its metabolites in breast milk are small and generally are not expected to be a risk for the infant.

Pediatrics: Children should be given reduced doses commensurate with their age, weight and physical condition because they may be more sensitive to systemic effects due to increased blood levels of lidocaine following repeated doses (see DOSAGE AND ADMINISTRATION).

In children, the dosage should be calculated on a weight basis up to 5 mg/kg (see DOSAGE AND ADMINISTRATION).

Lidocaine should be used with caution in children under the age of 2 as there is insufficient data to support the safety and efficacy of this product in this patient population at this time.

Geriatrics: Elderly patients may be more sensitive to systemic effects due to increased blood levels of lidocaine following repeated doses and may require dose reductions.

Carcinogenesis and Mutagenesis

Genotoxicity tests with lidocaine showed no evidence of mutagenic potential. A metabolite of lidocaine, 2,6-dimethylaniline, showed weak evidence of activity in some genotoxicity tests. A chronic oral toxicity study of the metabolite 2,6-dimethylaniline (0, 14, 45, 135 mg/kg) administered in feed to rats showed that there was a significantly greater incidence of nasal cavity tumours in male and female animals that had daily oral exposure to the highest dose of 2,6-dimethylaniline for 2 years. The lowest tumour-inducing dose tested in animals (135 mg/kg) corresponds to approximately 11 times the amount of 2,6-dimethylaniline to which a 50 kg subject would be exposed following a single injection of 600 mg of lidocaine for injection, assuming 80% conversion to 2,6-dimethylaniline. Based on a yearly exposure (once daily dosing with 2,6-dimethylaniline in animals and 5 treatment sessions with 600 mg lidocaine for injection in humans), the safety margins would be approximately 1000 times when comparing the exposure in animals to man.

ADVERSE REACTIONS

Adverse experiences following the administration of lidocaine are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by overdosage, rapid absorption, or inadvertent intravascular injection, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient.

Table 1 Adverse Drug Reaction Frequencies

Common ($\geq 1\%$ and $<10\%$)	<ul style="list-style-type: none">• Vascular Disorders: Hypotension, hypertension• Gastrointestinal Disorders: Nausea, vomiting• Nervous System Disorders: Paresthesia, dizziness• Cardiac Disorders: Bradycardia
Uncommon ($\geq 0.1\%$ and $<1\%$)	<ul style="list-style-type: none">• Nervous System Disorders: Signs and symptoms of CNS toxicity (convulsions, paresthesia circumoral, numbness of the tongue, hyperacusis, visual disturbances, tremor, tinnitus, dysarthria, CNS depression)
Rare ($\geq 0.01\%$ and $<0.1\%$)	<ul style="list-style-type: none">• Cardiac Disorders: Cardiac arrest, cardiac arrhythmias• Immune System Disorders: allergic reactions, anaphylactic reaction/shock• Respiratory Disorders: Respiratory depression• Nervous System Disorders: Neuropathy, peripheral nerve injury, arachnoiditis• Eye Disorders: Diplopia

Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported:

Central Nervous System: CNS manifestations are excitatory and/or depressant and may be characterized by the following signs and symptoms of escalating severity: circumoral paresthesia, light-headedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, hyperacusis, tinnitus, blurred vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. The excitatory manifestations (e.g., twitching, tremors, convulsions) may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest.

Drowsiness following the administration of lidocaine is usually an early sign of a high lidocaine plasma level and may occur as a consequence of rapid absorption.

Cardiovascular System: Cardiovascular manifestations are usually depressant and are characterized by bradycardia, hypotension, arrhythmia and cardiovascular collapse, which may lead to cardiac arrest.

Allergic: Allergic reactions are characterized by cutaneous lesions, urticaria, edema, or in the most severe instances, anaphylactic shock. Allergic reactions of the amide type are rare (< 0.1%) and may occur as a result of sensitivity either to the local anesthetic agent or to other components in the formulation (see DOSAGE FORMS, COMPOSITION AND PACKAGING).

Neurologic: The incidences of adverse reactions may be related to the total dose of local anesthetic administered but is also dependent upon the particular drug used, the route of administration and the physical status of the patient. Neuropathy and spinal cord dysfunction (e.g., anterior spinal artery syndrome, arachnoiditis, cauda equina syndrome), have been associated with regional anesthesia. Neurological effects may be related to local anesthetic techniques, with or without a contribution from the drug.

In the practice of lumbar epidural block, occasional unintentional penetration of the subarachnoid space by the catheter or needle may occur. For example, a high spinal is characterized by paralysis of the legs, loss of consciousness, respiratory paralysis and bradycardia.

Neurologic effects following unintentional subarachnoid administration during epidural anesthesia may include spinal block by varying magnitude (including total or high spinal block), hypotension secondary to spinal block, urinary retention, fecal and urinary incontinence, loss of perineal sensation and sexual function, persistent anesthesia, paresthesia, weakness, paralysis of the lower extremities and loss of sphincter control, all of which may have slow, incomplete or no recovery; headache, backache, septic meningitis, meningismus, slowing of labour, increased incidence of forceps delivery, or cranial nerve palsies due to traction on nerves from loss of cerebrospinal fluid.

DRUG INTERACTIONS

Overview

Lidocaine is mainly metabolized in the liver by CYP1A2 and CYP3A4 to its two major metabolites, monoethylglycinexylidide (MEGX) and glycinexylidide (GX), both of which are pharmacologically active. Lidocaine has a high hepatic extraction ratio. Only a small fraction (3%) of lidocaine is excreted unchanged in the urine. The hepatic clearance of lidocaine is expected to depend largely on blood flow.

Strong inhibitors of CYP1A2, such as fluvoxamine, given concomitantly with lidocaine, can cause a metabolic interaction leading to an increased lidocaine plasma concentration. Therefore, prolonged administration of lidocaine should be avoided in patients treated with strong inhibitors of CYP1A2, such as fluvoxamine. When co-administered with intravenous lidocaine, two strong inhibitors of CYP3A4, erythromycin and itraconazole, have each been shown to have a modest effect on the pharmacokinetics of intravenous lidocaine. Other drugs such as propranolol and cimetidine have been reported to reduce intravenous lidocaine clearance, probably through effects on hepatic blood flow and/or metabolism.

Clinically relevant pharmacodynamic drug interactions may occur with lidocaine and other local anesthetics or structurally related drugs, and Class I and Class III antiarrhythmic drugs due to additive effects.

Drug-Drug Interactions

Local Anesthetics and Agents Structurally Related to Amide-type Local Anesthetics

Lidocaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics (e.g., antiarrhythmics such as mexiletine), since the toxic effects are additive.

Antiarrhythmic Drugs

Class I Antiarrhythmic Drugs

Class I antiarrhythmic drugs (such as mexiletine) should be used with caution since toxic effects are additive and potentially synergistic.

Class III Antiarrhythmic Drugs

Caution is advised when using Class III antiarrhythmic drugs concomitantly with lidocaine due to potential pharmacodynamic or pharmacokinetic interactions with lidocaine, or both. A drug interaction study has shown that the plasma concentration of lidocaine may be increased following administration of a therapeutic dose of intravenous lidocaine to patients treated with amiodarone (n=6). Case reports have described toxicity in patients treated concomitantly with lidocaine and amiodarone. Patients treated with Class III antiarrhythmic drugs (e.g., amiodarone) should be kept under close surveillance and ECG monitoring should be considered, since cardiac effects of these drugs and lidocaine may be additive.

Strong Inhibitors of CYP1A2 and CYP3A4

Cytochrome CYP1A2 and CYP3A4 are involved in the formation of the pharmacologically active lidocaine metabolite MEGX.

Fluvoxamine: Strong inhibitors of CYP1A2, such as fluvoxamine, given during prolonged administration of lidocaine to areas with a high extent of systemic absorption can cause a metabolic interaction leading to an increased lidocaine plasma concentration. The plasma clearance of a single intravenous dose of lidocaine was reduced by 41 to 60% during co-administration of fluvoxamine, a selective and potent CYP1A2 inhibitor, to healthy volunteers.

Erythromycin and Itraconazole: Erythromycin and itraconazole, which are strong inhibitors of CYP3A4, have been shown to reduce clearance of lidocaine by 9 to 18%, following a single intravenous dose of lidocaine to healthy volunteers.

During combined co-administration with fluvoxamine and erythromycin, the plasma clearance of lidocaine was reduced by 53%.

β-blockers and Cimetidine

Following a single intravenous dose of lidocaine, administered to healthy volunteers, the clearance of lidocaine has been reported to be reduced up to 47% when co-administered with propranolol and up to 30% when co-administered with cimetidine. Reduced clearance of lidocaine when co-administered with these drugs is probably due to reduced liver blood flow and/or inhibition of microsomal liver enzymes. The potential for clinically significant interactions with these drugs should be considered during long-term treatment with high doses of lidocaine.

Monoamine Oxidase (MAO) Inhibitors

Solutions containing lidocaine and another vasoconstrictor should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAO) because severe prolonged hypertension may result. In situations when concurrent therapy is necessary, careful patient monitoring is essential.

Antidepressants (tricyclic, imipramine)

Solutions containing lidocaine and another vasoconstrictor should be used with extreme caution in patients receiving antidepressants of the tricyclic or imipramine types because severe prolonged hypertension may result. In situations when concurrent therapy is necessary, careful patient monitoring is essential.

Antipsychotics (phenothiazines, butyrophenones)

Solutions containing lidocaine and another vasoconstrictor should be used with extreme caution in patients receiving phenothiazines and butyrophenones. Phenothiazines and butyrophenones may oppose the vasoconstrictor effects of epinephrine giving rise to hypotensive responses and tachycardia. In situations when concurrent therapy is necessary, careful patient monitoring is essential.

Sedatives

If sedatives are employed to reduce patient apprehension, they should be used in reduced doses, since local anesthetic agents, like sedatives, are central nervous system depressants which in combination may have an additive effect.

Drug-Food Interactions

Interactions of lidocaine with food have not been established.

Drug-Herb Interactions

Interactions of lidocaine with herbal products have not been established.

Drug-Laboratory Tests Interactions

The intramuscular injection of lidocaine may result in an increase in creatine phosphokinase levels. Thus, the use of this enzyme determination, without isoenzyme separation, as a diagnostic test for the presence of acute myocardial infarction may be compromised by the intramuscular injection of lidocaine.

Drug-Lifestyle Interactions

Driving and Operating Machinery: Besides the direct anesthetic effect, local anesthetics may have a very mild effect on mental function and coordination even in the absence of overt CNS toxicity and may temporarily impair locomotion and alertness. Patients should be cautioned about driving a vehicle or operating potentially hazardous machinery on the day they receive local anesthetic treatment.

DOSAGE AND ADMINISTRATION

Dosing Considerations

General

Lidocaine Hydrochloride Injection USP should only be used by or under the supervision of clinicians experienced in regional anesthesia.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Solutions which are discoloured or which contain particulate matter should not be administered.

There have been adverse event reports of irreversible chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. Lidocaine Hydrochloride Injection USP is not approved for this use (see WARNINGS AND PRECAUTIONS: General).

Recommended doses serve only as a guide to the amount of anesthetic required for most routine procedures. The actual volumes and concentrations to be used depend on a number of factors such as type and extent of surgical procedure, depth of anesthesia and degree of muscular relaxation required, duration of anesthesia required, and the physical condition of the patient (see Special Populations).

The lowest concentration of anesthetic and the lowest dosage needed to provide effective anesthesia should be administered. The rapid injection of a large volume of local anesthetic solution should be avoided and fractional doses should be used when feasible.

When Lidocaine Hydrochloride Injection USP is used concomitantly with other products containing lidocaine, the total dose contributed by all formulations must be kept in mind.

Preservative-containing solutions (i.e., those supplied in multidose vials) should not be used for epidural or spinal anesthesia or for any route of administration that would introduce solution into the cerebrospinal fluid. Local anesthetic solutions containing antimicrobial preservatives should not be administered intra-ocularly or retro-ocularly. These solutions should not be used in doses greater than 15 mL for other types of blockades (see CONTRAINDICATIONS).

Special Populations

Lidocaine should be used with caution in patients with epilepsy, impaired cardiac conduction, bradycardia, impaired hepatic or renal function and in severe shock (see WARNINGS AND PRECAUTIONS).

Debilitated patients, elderly patients, acutely ill patients, patients with sepsis and children should be given reduced doses commensurate with their age, weight and physical condition (see WARNINGS AND PRECAUTIONS).

Recommended Dose and Dosage Adjustment

Careful aspiration before and during injection is recommended to prevent intravascular injection. The main dose should be injected slowly or in incremental doses, while closely observing the patient's vital functions and maintaining verbal contact.

Adults: Table 2 (Recommended Dosages) summarizes the recommended volumes and concentrations of Lidocaine Hydrochloride Injection USP for various types of anesthetic procedures. The dosages suggested in this table are for normal healthy adults and refer to the use of epinephrine-free solutions. When larger volumes are required, only solutions containing epinephrine should be used except in those cases where vasopressor drugs may be contraindicated.

Children: In children, the dosage should be calculated on a weight basis up to 5 mg/kg. Individual variations occur. In children with a high body weight, a gradual reduction of the dosage is often necessary and should be based on the ideal body weight. Standard textbooks

should be consulted for factors affecting specific block techniques and for individual patient requirements.

The onset of anesthesia, the duration of anesthesia and the degree of muscular relaxation are proportional to the volume and concentration (i.e. total dose) of local anesthetic used. Thus, an increase in volume and concentration of Lidocaine Hydrochloride Injection USP will decrease the time to onset of anesthesia, prolong the duration of anesthesia, provide a greater degree of muscular relaxation and increase the segmental spread of anesthesia. However, increasing the volume and concentration of Lidocaine Hydrochloride Injection USP may result in a more profound fall in blood pressure when used in epidural anesthesia. Although the incidence of side effects with lidocaine hydrochloride is quite low, caution should be exercised when employing large volumes and concentrations since the incidence of side effects is directly proportional to the total dose of local anesthetic agent injected. The risk of reaching a toxic plasma concentration or inducing a local neural injury must be considered when prolonged blocks and/or repeated administration are employed.

In general, complete block of all nerve fibres in large nerves requires the higher concentrations of drug. In smaller nerves, or when a less intense block is required (e.g., in the relief of labour pain), the lower concentrations are indicated. The volume of drug used will affect the extent of spread of anesthesia.

The duration of effect can be increased by using solutions containing epinephrine. The risk of epinephrine systemic effects with solutions containing large volumes of epinephrine should be considered.

Epidural Anesthesia

The lowest dosage that will produce the desired effect should be given. The amount varies with the number of dermatomes to be anesthetized (generally 2 to 3 mL of the indicated concentration per dermatome). Solutions with preservatives (methylparaben) should not be used since their safety has not been established.

Caudal and Lumbar Epidural Block

Patients on beta blockers may not manifest changes in heart rate, but blood pressure monitoring can detect an evanescent rise in systolic blood pressure. Adequate time should be allowed for onset of anesthesia after administration of each test dose. The rapid injection of a large volume of Lidocaine Hydrochloride Injection USP through the catheter should be avoided and when feasible, fractional doses should be administered.

The main dose should be injected slowly at a rate of 100 to 200 mg/min, or in incremental doses, while keeping in constant verbal contact with the patient. If toxic symptoms occur, the injection should be stopped immediately.

In the event of the known injection of a large volume of local anesthetic solution into the subarachnoid space, after suitable resuscitation and if the catheter is in place, consider attempting

the recovery of drug by draining a moderate amount of cerebrospinal fluid (such as 10 mL) through the epidural catheter.

Table 2 Dosage Recommendations in Adults

Type of Block	Conc. (%)	Each Dose ¹		Onset (min)	Duration (h)	Indication
		mL	mg			
Local infiltration	0.5	≤ 80	≤ 400	1-2	1.5-2	Surgical operations.
	1	≤ 40	≤ 400	1-2	2-3	
Digital ²	1	1-5	10-50	2-5	1.5-2	
Intercostal (per nerve) Maximum total dose of 480 mg	1	2-5	20-50	3-5	1-2	Surgical operations, postoperative pain and fractured ribs.
	1.5	2-4	30-60	3-5	2-3	
Paracervical ³ (each side)	1	10	100	3-5	1-1.5	Surgical operations and dilation of cervix. Obstetric pain relief.
Paravertebral (per segment)	1	3-5	30-50	5-10	1-1.5	Pain management, diagnostic.
	2	3-5	60-100	5-10	1.5-2	
Pudendal (each side)	1	10	100	5-10	1.5-2	Instrumental delivery.
Intra-articular block ⁴	0.5	≤ 60	≤ 300	5-10	0.5-1 after washout	Arthroscopy and surgical operations.
	1	≤ 40	≤ 400	5-10		
Retrobulbar ³	2	4	80	3-5	1.5-2	Ocular surgery.
Peribulbar ³	1	10-15	100-150	3-5	1.5-2	
Axillary	1.0	40-50	400-500	15-30	1.5-2	Surgical operations.
	1.5	30-50	450-600	15-30	1.5-3	
Supraclavicular interscalene and subclavian perivascular	1.0	30-40	300-400	15-30	1.5-2	
	1.5	20-30	300-450	15-30	1.5-3	
Sciatic	1.5	15-20	225-300	15-30	2-3	
	2	15-20	300-400	15-30	2-3	
3-in-1 (Femoral, obturator and lateral cutaneous)	1	30-40	300-400	15-30	1.5-2	
	1.5	30	450	15-30	2-3	
Epidural	1	5	50			Test dose.
	1.5	3-5	45-75			
	2	3	60			
Lumbar epidural ¹	2	15-25	300-500	15-20	1.5-2	Surgical operations.
Thoracic epidural ¹	1.5	10-15	150-225	10-20	1-1.5	Surgical operations and pain relief.

Type of Block	Conc. (%)	Each Dose ¹		Onset (min)	Duration (h)	Indication
		mL	mg			
	2	10-15	200-300	10-20	1.5-2	Surgical operations.
Caudal epidural ¹	1	20-30	200-300	15-30	1-1.5	Surgical operations and pain relief.
	2	15-25	300-500	15-30	1.5-2	Surgical operations.

¹ For epidural blocks, dose includes test dose.

² Without epinephrine.

³ See WARNINGS AND PRECAUTIONS.

⁴ There have been post-marketing reports of irreversible chondrolysis in patients receiving post-operative intra-articular infusion of local anesthetics. Lidocaine Hydrochloride Injection USP is not approved for this indication (see WARNINGS AND PRECAUTIONS).

OVERDOSAGE

For management of a suspected drug overdose, contact your regional Poison Control Centre.

Acute systemic toxicity from local anesthetics is generally related to high plasma levels encountered during therapeutic use of local anesthetics and originates mainly in the central nervous and the cardiovascular systems (see ADVERSE REACTIONS and WARNINGS AND PRECAUTIONS). It should be kept in mind that clinically relevant pharmacodynamic drug interactions (i.e., toxic effects) may occur with lidocaine and other local anesthetics or structurally related drugs, and Class I and Class III antiarrhythmic drugs due to additive effects (see DRUG INTERACTIONS).

Symptoms

With accidental intravascular injections, the toxic effect will be obvious within 1 to 3 min, while with overdosage, peak plasma concentrations may not be reached for 20 to 30 min depending on the site of injection, with signs of toxicity thus being delayed.

Central nervous system toxicity is a graded response, with symptoms and signs of escalating severity. The first symptoms are circumoral paresthesia, numbness of the tongue, lightheadedness, hyperacusis and tinnitus. Visual disturbance and muscular tremors are more serious and precede the onset of generalized convulsions. Unconsciousness and grand mal convulsions may follow, which may last from a few seconds to several minutes. Hypoxia and hypercarbia occur rapidly following convulsions due to the increased muscular activity, together with the interference with normal respiration. In severe cases, apnea may occur. Acidosis, hyperkalemia, hypocalcemia and hypoxia increase and extend the toxic effects of local anesthetics.

Recovery is due to redistribution and metabolism of the local anesthetic drug. Recovery may be rapid unless large amounts of the drug have been administered.

Cardiovascular effects may be seen in cases with high systemic concentrations. Severe hypotension, bradycardia, arrhythmia and cardiovascular collapse may be the result in such cases.

Cardiovascular toxic effects are generally preceded by signs of toxicity in the central nervous system, unless the patient is receiving a general anesthetic or is heavily sedated with drugs such as a benzodiazepine or barbiturate.

Treatment

The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient's state of consciousness after each local anesthetic administration. At the first sign of change, oxygen should be administered. **If signs of acute systemic toxicity appear, injection of the local anesthetic should be immediately stopped.**

The first step in the management of systemic toxic reactions, as well as underventilation or apnea due to unintentional subarachnoid injection consists of immediate attention to the establishment and maintenance of a patent airway and assisted or controlled ventilation with oxygen and a delivery system capable of permitting immediate positive airway pressure by mask. This may prevent convulsions if they have not already occurred.

If convulsions occur, the objective of the treatment is to maintain ventilation and oxygenation and support circulation. Oxygen must be given and ventilation assisted if necessary (mask and bag or tracheal intubation). Should convulsions not stop spontaneously after 15 to 20 seconds, an anticonvulsant should be given intravenously to facilitate adequate ventilation and oxygenation. Thiopental sodium 1-3 mg/kg intravenous is the first choice. Alternatively, diazepam 0.1 mg/kg bw intravenous may be used, although its action will be slow. Prolonged convulsions may jeopardize the patient's ventilation and oxygenation. If so, injection of a muscle relaxant (e.g., succinylcholine 1 mg/kg bw) will facilitate ventilation, and oxygenation can be controlled. Early endotracheal intubation is required when succinylcholine is used to control motor seizure activity.

If cardiovascular depression is evident (hypotension, bradycardia), it should be managed according to the patient condition and standard of anaesthetic care.

Should circulatory arrest occur, immediate cardiopulmonary resuscitation should be instituted. Continual oxygenation, ventilation, circulatory support as well as treatment of acidosis are of vital importance, since hypoxia and acidosis will increase the systemic toxicity of local anesthetics. Epinephrine (0.1 to 0.2 mg as intravenous or intracardial injections) should be given as soon as possible and repeated, if necessary.

Children should be given doses of epinephrine commensurate with their age and weight.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Local anesthetics of the amide type are thought to act within the sodium channels of the nerve membrane.

Onset of Action

The onset of action is 1 to 5 minutes following infiltration and 5 to 15 minutes following other types of administration. The duration of anesthesia depends on the concentration of lidocaine used, the dose, and the type of block. The 2% solution will last 1½ to 2 hours when given by epidural injection, and up to 5 hours with peripheral nerve blocks. With the 1% concentration, there is less effect on motor nerve fibres and the duration of action is shorter.

Hemodynamics

Lidocaine, like other local anesthetics, may also have effects on other excitable membranes (e.g., brain and myocardium). If excessive amounts of drug reach systemic circulation, symptoms and signs of toxicity may appear, emanating from the central nervous and cardiovascular systems.

Central nervous system toxicity (see OVERDOSAGE) usually precedes the cardiovascular effects since it occurs at lower plasma concentrations. Direct effects of local anesthetics on the heart include slow conduction, negative inotropism and eventually cardiac arrest.

Indirect cardiovascular effects (hypotension, bradycardia) may occur after epidural administration depending on the extent of the concomitant sympathetic block.

Pharmacokinetics

Absorption: Lidocaine is completely absorbed following parenteral administration. The rate of absorption depends on the dose, route of administration, and the vascularity of the injection site. The highest peak plasma levels are obtained following intercostal nerve block (approximately 1.5 mcg/mL per 100 mg injected) while abdominal subcutaneous injections give the lowest (approximately 0.5 mcg/mL per 100 mg injected). Epidural and major nerve blocks are intermediate.

Lidocaine shows complete and biphasic absorption from the epidural space with half-lives of the two phases in the order of 9.3 minutes and 82 minutes respectively. The slow absorption is the rate-limiting factor in the elimination of lidocaine, which explains why the apparent terminal half-life is longer after epidural administration. Absorption of lidocaine from the subarachnoid space is monophasic with an absorption half-life of 71 minutes.

Distribution: Lidocaine has a total plasma clearance of 0.95 L/min and a volume of distribution at steady state of 91 L.

Lidocaine readily crosses the placenta, and equilibrium with regard to the unbound concentration is rapidly reached. The degree of plasma protein-binding in the fetus is less than in the mother, which results in lower total plasma concentrations in the fetus.

The plasma protein-binding of lidocaine is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1 to 4 mcg of free base per mL, 60 to 80% of lidocaine is protein-bound. Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein.

Metabolism: Lidocaine is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys. The main metabolites formed from lidocaine are monoethylglycinexylidide (MEGX), glycinexylidide (GX), 2,6-dimethylaniline and 4-hydroxy-2,6-dimethylaniline. The N-dealkylation to MEGX is considered to be mediated by both CYP1A2 and CYP3A4. The metabolite 2,6-dimethylaniline is converted to 4-hydroxy-2,6-dimethylaniline by CYP2A6, and the latter is the major urinary metabolite in man. Only 3% of lidocaine is excreted unchanged. About 70% appears in the urine as 4-hydroxy-2,6-dimethylaniline.

Excretion: Lidocaine has a terminal half-life of 1.6 hours and an estimated hepatic extraction ratio of 0.65. The clearance of lidocaine is almost entirely due to liver metabolism, and depends both on liver blood flow and the activity of metabolizing enzymes.

The pharmacological/toxicological actions of MEGX and GX are similar to, but less potent than those of lidocaine. GX has a longer half-life (about 10 hours) than lidocaine and may accumulate during long-term administration.

The elimination half-life of lidocaine following an intravenous bolus injection is typically 1.5 to 2.0 hours. The terminal half-life in neonates (3.2 hours) is approximately twice that of adults, whereas clearance is similar (10.2 mL/min/kg). The half-life may be prolonged two-fold or more in patients with liver dysfunction. Renal dysfunction does not affect lidocaine kinetics but may increase the accumulation of metabolites.

Special Populations and Conditions

Acidosis increases the systemic toxicity of lidocaine while the use of CNS depressants may increase the levels of lidocaine required to produce overt CNS effects. Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6.0 mcg free base per mL.

STORAGE AND STABILITY

Lidocaine Hydrochloride Injection USP should be stored at controlled room temperature (20°C to 25°C). Protect from freezing.

SPECIAL HANDLING INSTRUCTIONS

Sterilization and Technical Procedures

When chemical disinfection of multidose vials is desired, either isopropyl alcohol (70%) or ethyl alcohol (70%) is recommended. Many commercially available brands of rubbing alcohol, as well as solutions of ethyl alcohol not of USP grade, contain denaturants which are injurious to rubber and therefore are not to be used.

The solubility of lidocaine is limited at pH>6.5. This must be taken into consideration when alkaline solutions, i.e., carbonates, are added, since precipitation might occur.

Lidocaine hydrochloride plain solutions in some glass vial presentations may be autoclaved (refer to product label for confirmation) for 15 to 20 minutes at 121°C.

Do not use if solution is coloured or if it contains a precipitate.

Lidocaine Hydrochloride Injection USP without preservative is for single use only. Discard unused portion. The multidose vials should not be used for more than three days after the container has been opened for the first time.

There is a greater risk of microbial contamination with multidose vials than with single-dose vials. Single-dose vials should therefore be used whenever possible. If a multidose vial is used, appropriate control procedures to prevent contamination should be employed, including the following:

- Use of single-use sterile injecting equipment;
- Use of a sterile needle and syringe for each insertion into the vial;
- Rule out the introduction of contaminated material or fluid into a multidose vial.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Dosage Forms

Lidocaine Hydrochloride Injection USP is a sterile solution.

Composition

Medicinal Ingredients

Lidocaine hydrochloride 10 mg/mL and 20 mg/mL.

Non-Medicinal Ingredients

Sodium chloride (for isotonicity), water for injection, sodium hydroxide and/or hydrochloric acid to adjust pH 5.0 to 7.0. Multidose vials contain methylparaben (as a preservative) 1 mg/mL.

Packaging

The packaging configurations for Lidocaine Hydrochloride Injection USP are as follows:

- 10 mg/mL: 2 mL in single-use ampoules; 20 mL in multidose vials
- 20 mg/mL: 2 mL in single-use ampoule; 20 mL and 50 mL in multidose vials

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance


Proper Name: Lidocaine hydrochloride USP

Chemical Name: 2-Diethylamino-N-(2,6-dimethylphenyl)-acetamide monohydrochloride monohydrate

Molecular Formula: $C_{14}H_{22}N_2O \cdot HCl \cdot H_2O$

Molecular Mass: 288.8 g/mol

Structural Formula:



Physicochemical Properties: White crystalline powder. Very soluble in water, freely soluble in alcohol. Melting range between 74 and 79°C. pH of 4.0 to 5.5 (0.5% solution in H₂O).

REFERENCES

1. Bailie D, Ellenbecker T. Severe chondrolysis after shoulder arthroscopy: A case series. *J Shoulder Elbow Surg* 2009;18(5):742-747.
2. McNickle A, L'Heureux D, Provencher M, Romeo A, Cole B. Postsurgical Glenohumeral Arthritis in Young Adults. *Am J Sports Med* 2009; 37(9):1784-1791.
3. Solomon D, Navaie M, Stedje-Larsen E, Smith J, Provencher M. Glenohumeral Chondrolysis After Arthroscopy: A Systematic Review of Potential Contributors and Causal Pathways. *J Arthr Rel Surg* 2009; 25(11):1329-1342.
4. XYLOCAINE[®] Parenteral Solutions. Prescribing Information. AstraZeneca Canada Inc. June 26, 2018, control number 213919.

PART III: CONSUMER INFORMATION**Lidocaine Hydrochloride Injection USP**

10 mg/mL, 20 mg/mL

Sterile Solution

Local Anesthetic

This leaflet is part III of a three-part “Package Insert” published when Lidocaine Hydrochloride Injection USP was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about Lidocaine Hydrochloride Injection USP. Contact your doctor if you have any questions about the drug.

ABOUT THIS MEDICATION**What the medication is used for:**

Lidocaine Hydrochloride Injection USP is used to anesthetize part of the body for surgical operations and also for pain relief and can be used:

- To anesthetize the area of the body where surgery is to be performed;
- To provide pain relief in labour and after surgery.

What it does:

Lidocaine Hydrochloride Injection USP acts by preventing the nerves in the injected area from transmitting sensations of pain, heat or cold. However, you may still experience sensations such as pressure and touch. In this way, the nerve(s) is anesthetized in the part of the body, which will be subjected to surgery. In many cases this means that the nerves to the muscles in the area will also be blocked, causing temporary weakness or paralysis.

When it should not be used:

Lidocaine Hydrochloride Injection USP should not be used in patients who:

- are allergic to lidocaine, any other “-caine” type anesthetics, or any of the non-medicinal ingredients in the product (see **Non-medicinal ingredients** below);
- are allergic to methylparaben (preservative used in some solutions) or PABA.

Lidocaine Hydrochloride Injection USP containing methylparaben should not be used for epidural or spinal anesthesia.

Because of the potential for irreversible joint damage, pain following joint surgery should not be managed by infusing Lidocaine Hydrochloride Injection USP into the joint (i.e., by use of a post-operative “pain pump”).

What the medicinal ingredients are:

Sterile solutions of Lidocaine Hydrochloride Injection USP contains 10 mg/mL and 20 mg/mL lidocaine hydrochloride.

Non-medicinal ingredients:

Lidocaine Hydrochloride Injection USP also contains sodium chloride, water for injection, and sodium hydroxide and/or hydrochloric acid.

Multidose vials contain methylparaben.

Check with your doctor if you think you may be sensitive to any of the above ingredients.

What dosage forms it comes in:

Lidocaine Hydrochloride Injection USP is available in single-use ampoules and multidose vials.

WARNINGS AND PRECAUTIONS

You should talk to your doctor prior to surgery:

- about all health problems you have now or have had in the past;
- about other medicines you take, including ones you can buy without a prescription;
- if you are taking other medicines such as drugs used to treat irregular heart activity (anti-arrhythmics);
- if you think you may be allergic or sensitive to any ingredients in Lidocaine Hydrochloride Injection USP (see above);
- if you have a severe heart, kidney or liver disease;
- if you have neurological disease, spinal deformities, septicemia and severe hypertension (in case of lumbar and caudal epidural anesthesia);
- if you have epilepsy;
- if you or someone in your family has been diagnosed with porphyria;
- if you are experiencing severe shock;
- if you are pregnant, plan to become pregnant or are breastfeeding;
- if you are planning to drive or operate any tools or machinery on the day of surgery, because Lidocaine Hydrochloride Injection USP may temporarily interfere with your reactions and muscle coordination.

INTERACTIONS WITH THIS MEDICATION

Tell your doctor/dentist/pharmacist if you are taking or have recently taken any medicines, even those that can be bought without a prescription.

Drugs that may interact with Lidocaine Hydrochloride Injection USP include:

- anti-arrhythmic drugs for heart problems (e.g., mexiletine, amiodarone);
- other anesthetics;
- propranolol for heart problems or cimetidine for gastrointestinal problems;
- fluvoxamine for depression, if using high doses of Lidocaine Hydrochloride Injection USP for a long time and other medicines for depression;
- antimigraine therapy;
- antipsychotic therapy;
- medicines for high blood pressure.

Usage of such medicines at the same time as Lidocaine Hydrochloride Injection USP may increase the risk of serious side effects.

PROPER USE OF THIS MEDICATION

Usual dose:

Lidocaine Hydrochloride Injection USP should be administered by a doctor. The dose to be given is decided by the doctor, based on the clinical need and your physical condition.

Overdose:

If you think you have taken too much Lidocaine Hydrochloride Injection USP, contact your health care professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Serious side effects resulting from getting too much Lidocaine Hydrochloride Injection USP need special treatment and the doctor treating you is trained to deal with these situations. Early signs that too much Lidocaine Hydrochloride Injection USP has been given include:

- numbness of the lips and around the mouth
- light-headedness or dizziness
- blurred vision
- hearing problems
- tingling in the ears

In the event of a serious overdosage or a misplaced injection, trembling, seizures or unconsciousness may occur.

If the early signs of overdosage are noticed and no further Lidocaine Hydrochloride Injection USP is given, the risk of serious side effects occurring rapidly decreases. If you have any of these symptoms, or you think you have received too much Lidocaine Hydrochloride Injection USP, **tell your doctor immediately.**

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like any medication, Lidocaine Hydrochloride Injection USP may cause side effects in some people.

Medicines affect different people in different ways. Just because side effects have occurred in some patients, does not mean that you will get them. If any side effects bother you, or if you experience any unusual effects after exposure to Lidocaine Hydrochloride Injection USP, check with your doctor as soon as possible.

Lidocaine Hydrochloride Injection USP may temporarily interfere with your reactions and muscle co-ordination; therefore do not drive or use machines on the day of surgery.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom / effect	Talk with your doctor or pharmacist		Stop taking the drug and get immediate medical help
	Only if severe	In all cases	
Common			
Dizziness, abnormal sensations (pins and needles)		√	
Feeling of sickness/nausea*, vomiting*	√		
Decreased heart rate		√	
Increased blood pressure, decreased blood pressure*		√	
Uncommon			
Toxicity symptoms such as: convulsions, seizures, light-headedness, numbness of the lips and around the mouth, numbness of the tongue, hearing disturbances, visual disturbances, speech disturbances, trembling and other signs of central nervous system depression.			√
Rare			
Cardiac arrest and/or irregular heartbeat			√
Allergic reactions such as: facial swelling and difficulties with breathing/respiratory shock			√
Nervous system disorders such as: nerve injury, paralysis or tingling of extremities		√	
Double vision		√	

* These side effects occur more frequently after epidural block.

Last revised: July 2, 2019

This is not a complete list of side effects. Consult your doctor immediately if any of these symptoms or any unexpected effects appear.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on [Adverse Reaction Reporting \(https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html\)](https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

HOW TO STORE IT

Lidocaine Hydrochloride Injection USP should be stored at controlled room temperature (20°C to 25°C). Protect from freezing. Keep out of the reach and sight of children.

Your doctor or the hospital will normally store Lidocaine Hydrochloride Injection USP. The staff is responsible for storing, dispensing and disposing of Lidocaine Hydrochloride Injection USP in the correct way.

MORE INFORMATION

Important Note: This leaflet alerts you to some of the times you should call your doctor. Other situations which cannot be predicted may arise. Nothing about this leaflet should stop you from calling your doctor with any questions or concerns you have about using Lidocaine Hydrochloride Injection USP.

NOTE: This CONSUMER INFORMATION leaflet provides you with the most current information at the time of printing.

This document, plus the full Prescribing Information prepared for health professionals, can be found by contacting the sponsor, Pfizer Canada ULC, at: 1-800-463-6001.

This leaflet was prepared by:
Pfizer Canada ULC
Kirkland, Québec H9J 2M5